Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of 31,101 restricted stock units (RSUs) to two new employees. The RSUs are structured to vest in four equal annual installments, with complete vesting occurring on the fourth anniversary of the grant date. The grants were issued under the Company's 2024 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an inducement for employment acceptance.
Solid Biosciences (SLDB), un'azienda delle scienze della vita focalizzata sullo sviluppo di medicinali genetici di precisione per malattie neuromuscolari e cardiache, ha annunciato l'assegnazione di 31.101 unità di azioni riservate (RSU) a due nuovi dipendenti. Le RSU sono strutturate per maturare in quattro quote annuali uguali, con la maturazione completa che si verifica al quarto anniversario della data di concessione. Le assegnazioni sono state emesse nell'ambito del Piano di Incentivi Azionari 2024 dell'azienda e sono conformi alla Regola 5635(c)(4) di Nasdaq, fungendo da incentivo per l'accettazione dell'impiego.
Solid Biosciences (SLDB), una empresa de ciencias de la vida centrada en el desarrollo de medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha anunciado la concesión de 31,101 unidades de acciones restringidas (RSUs) a dos nuevos empleados. Las RSUs están estructuradas para adquirirse en cuatro cuotas anuales iguales, con la adquisición completa ocurriendo en el cuarto aniversario de la fecha de concesión. Las concesiones se emitieron bajo el Plan de Incentivos de Acciones por Inducción 2024 de la empresa y cumplen con la Regla 5635(c)(4) de Nasdaq, sirviendo como un incentivo para la aceptación del empleo.
솔리드 바이오사이언스(SLDB)는 신경근육 및 심장 질환을 위한 정밀 유전자 의약품 개발에 집중하는 생명 과학 회사로, 두 명의 신입 직원에게 31,101 제한 주식 단위(RSU)를 부여한다고 발표했습니다. RSU는 4년의 동등한 연간 할당량으로 분할되어 만기가 도래하며, 완전한 귀속은 부여일의 4주년이 되는 시점에 이루어집니다. 이 부여는 회사의 2024 유인 주식 인센티브 계획에 따라 발행되었으며, Nasdaq의 목록 규칙 5635(c)(4)를 준수하여 고용 수락에 대한 유인을 제공합니다.
Solid Biosciences (SLDB), une entreprise de sciences de la vie axée sur le développement de médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a annoncé l'attribution de 31 101 unités d'actions restreintes (RSU) à deux nouveaux employés. Les RSU sont structurées pour acquérir en quatre versements annuels égaux, avec une acquisition complète se produisant au quatrième anniversaire de la date d'attribution. Les attributions ont été émises dans le cadre du Plan d'Incentives d'Actions 2024 de l'entreprise et respectent la règle d'inscription 5635(c)(4) de Nasdaq, servant d'incitation à l'acceptation de l'emploi.
Solid Biosciences (SLDB), ein Unternehmen der Life Sciences, das sich auf die Entwicklung von präzisen gentherapeutischen Mitteln gegen neurologische und Herzkrankheiten konzentriert, hat die Gewährung von 31.101 eingeschränkten Aktieneinheiten (RSUs) an zwei neue Mitarbeiter bekannt gegeben. Die RSUs sind so strukturiert, dass sie in vier gleichen jährlichen Raten erlangt werden, wobei die vollständige Zuteilung am vierten Jahrestag des Gewährungstags erfolgt. Die Zuteilungen wurden im Rahmen des 2024 Incentive Stock Plan des Unternehmens ausgegeben und entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und dienen als Anreiz zur Akzeptanz einer Anstellung.
- None.
- None.
CHARLESTOWN, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 31,101 restricted stock units (“RSUs”) to two newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
How many RSUs did Solid Biosciences (SLDB) grant to new employees in February 2024?
What is the vesting schedule for SLDB's February 2024 RSU grants?
Under which plan were SLDB's February 2024 RSU grants issued?
What are the vesting conditions for SLDB's February 2024 RSU grants?
